Peer-reviewed veterinary case report
N-terminal proatrial natriuretic peptide levels in cats with heart
By Zimmering, Tanja M et al.·Published in American journal of veterinary research·2009·Department of Small Animal Medicine and Surgery, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Measurement of N-terminal proatrial natriuretic peptide in plasma of cats with and without cardiomyopathy.
- Species:
- cat
Plain-English summary
A group of cats with heart disease (cardiomyopathy) were tested to see if a specific blood marker (N-terminal proatrial natriuretic peptide or Nt-proANP) could help identify those with heart failure. The study included 16 cats with cardiomyopathy but no heart failure, 16 with both conditions, and 11 healthy cats. The results showed that the blood levels of Nt-proANP were much higher in cats with both cardiomyopathy and heart failure compared to those with just cardiomyopathy or healthy cats. This suggests that measuring this marker could help vets assess heart disease in cats and differentiate between those with and without heart failure.
People also search for: cat heart disease symptoms · cardiomyopathy in cats treatment · high blood pressure in cats
Abstract
OBJECTIVE: To determine whether plasma N-terminal proatrial natriuretic peptide (Nt-proANP) concentrations in cats with cardiomyopathy (CM) differ from values in healthy cats and evaluate whether plasma Nt-proANP concentrations can be used to discriminate cats with CM and congestive heart failure (CHF) from CM-affected cats without CHF. ANIMALS: 16 cats that had CM without CHF, 16 cats that had CM with CHF, and 11 healthy control cats. PROCEDURES: All cats underwent a physical examination, assessment of clinicopathologic variables (including plasma thyroxine concentration), thoracic radiography, and echocardiography. On the basis of findings, cats were assigned to 1 of 3 groups (control cats, cats with CM and CHF, and cats with CM without CHF). Venous blood samples were obtained from all 43 cats, and plasma Nt-proANP concentrations were measured by use of a human proANP(1-98) ELISA. RESULTS: Plasma Nt-proANP concentrations differed significantly among the 3 groups. Median Nt-proANP concentration was 381 fmol/mL (range, 52 to 450 fmol/mL), 763 fmol/mL (range, 167 to 2,386 fmol/mL), and 2,443 fmol/mL (range, 1,189 to 15,462 fmol/mL) in the control group, in cats with CM without CHF, and in cats with CM and CHF, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: Measurement of plasma Nt-proANP concentration could be of benefit in the assessment of cats with naturally occurring CM and might have potential as a screening marker for the disease. Furthermore, measurement of plasma NtproANP concentration may be useful for distinguishing cats with CM and CHF from those with CM and no CHF.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19231954/